GLP-1 Medications for Seniors | Weight
US$ 27.69
comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice GLP-1 receptor agonists and next-generation
Description
The starting dose is deliberately conservative to allow for this dual adaptation
This dual action on both glycemic control and cardiovascular health has elevated GLP-1 receptor agonists to an important position in diabetes management
2% WL with placebo in people with obesity [68]
Another contraindication is the use of GLP-1RA in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2 (33, 34, 36)
J Hepatol (2019) 70:53144
